Molecular Partners (NASDAQ:MOLN – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.08, Zacks reports.
Molecular Partners Stock Performance
MOLN stock traded up $0.09 during midday trading on Friday, reaching $3.62. 1,753 shares of the company’s stock traded hands, compared to its average volume of 2,200. The company has a 50-day moving average price of $4.03 and a two-hundred day moving average price of $4.18. Molecular Partners has a 52 week low of $3.51 and a 52 week high of $5.36. The firm has a market capitalization of $146.16 million, a PE ratio of -2.15 and a beta of 1.11.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on MOLN shares. HC Wainwright restated a “buy” rating on shares of Molecular Partners in a research report on Monday, July 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a research note on Friday, October 2nd. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $8.38.
Get Our Latest Report on Molecular Partners
About Molecular Partners
Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland. The company develops therapeutic molecules based on its proprietary DARPin platform, which uses designed ankyrin repeat proteins to create targeted, multi-specific medicines intended to address complex disease pathways.
Molecular Partners’ research and development activities have focused primarily on oncology, ophthalmology and infectious diseases. Its pipeline has included experimental programs designed to engage multiple biological targets, with the goal of improving treatment effectiveness and addressing limitations associated with conventional antibody-based therapies.
Read More
- Five stocks we like better than Molecular Partners
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
